E-LIB Suche - Ergebnisse für: Tawbi, H.

1

Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib..:

Burton, E. ; Honaker, V. ; Milton, D....
EJC Skin Cancer. 2 (2024) - p. 100160 , 2024

Link: https://doi.org/10.1016/..

2

Efficacité et tolérance de l'association du nivolumab (NIVO..:

Tawbi, H. ; Forsyth, P. ; Hodi, F.S....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A333-A334 , 2019

Link: https://doi.org/10.1016/..

3

Advances in the systemic treatment of melanoma brain metast..:

Glitza Oliva, I.C. ; Schvartsman, G. ; Tawbi, H.
Annals of Oncology. 29 (2018) 7 - p. 1509-1520 , 2018

Link: https://doi.org/10.1093/..

4

A randomised phase II trial of selumetinib vs selumetinib p..:

Eroglu, Z ; Tawbi, H A ; Hu, J...
British Journal of Cancer. 112 (2015) 10 - p. 1644-1651 , 2015

Link: https://doi.org/10.1038/..

5

MC13-0078 PARP1 variants associated with response to Temozo..:

Sedgewick, A. ; Romkes, M. ; Buch, S....
European Journal of Cancer. 49 (2013) - p. S33-S34 , 2013

Link: https://doi.org/10.1016/..

6

Gut microbiota signatures are associated with toxicity to c..:

Andrews M. C ; Duong C. P. M ; Gopalakrishnan V...
info:eu-repo/semantics/altIdentifier/pmid/34239137. , 2021

Link: http://hdl.handle.net/11..

7

Calcium-sensing receptor autoantibody-mediated hypoparathyr..:

Dadu, R ; Rodgers, T.E ; Trinh, V.A...
https://eprints.whiterose.ac.uk/160473/8/e000687.full.pdf. , 2020

Link: https://eprints.whiteros..

8

Gut microbiome modulates response to anti–PD-1 immunotherap..:

Gopalakrishnan, V ; Spencer, C. N ; Nezi, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827966/. , 2017

Link: http://www.ncbi.nlm.nih...

9

A randomised phase II trial of selumetinib vs selumetinib p..:

Eroglu, Z ; Tawbi, H A ; Hu, J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430716/. , 2015

Link: http://www.ncbi.nlm.nih...

10

PD-1 and Tim-3 regulate the expansion of tumor antigen-spec..:

Fourcade, J ; Sun, Z ; Pagliano, O...
info:eu-repo/semantics/altIdentifier/doi/10.1158/0008-5472.CAN-13-2908. , 2014

Link: https://serval.unil.ch/n..

11

Role of PARP Inhibitors in Cancer Biology and Therapy:

Davar, D ; Beumer, J.H ; Hamieh, L.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421454. , 2012

Link: http://www.ncbi.nlm.nih...

12

Inhibition of DNA repair with MGMT pseudosubstrates: phase ..:

Tawbi, H A ; Villaruz, L ; Tarhini, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171007. , 2011

Link: http://www.ncbi.nlm.nih...

13

Short-term treatment with multi-drug regimens combining BRA..:

MG White ; R Szczepaniak Sloane ; RG Witt...
doi:10.26181/619c6e8861f65. , 2021

Link: https://doi.org/10.26181..

14

Short-term treatment with multi-drug regimens combining BRA..:

MG White (11742986) ; R Szczepaniak Sloane (11742989) ; RG Witt (11742992)...
https://figshare.com/articles/journal_contribution/Short-term_treatment_with_multi-drug_regimens_combining_BRAF_MEK-targeted_therapy_and_immunotherapy_results_in_durable_responses_in_Braf-mutated_melanoma/17065733. , 2021

Link: https://doi.org/10.26181..

15

A phase 1 study of veliparib (ABT-888) plus weekly carbopla..:

Malhotra, Monica K. ; Pahuja, Shalu ; Kiesel, Brian F....
Breast Cancer Research and Treatment. 198 (2023) 3 - p. 487-498 , 2023

Link: https://doi.org/10.1007/..